TRAIL Protein (AA 95-281, Extracellular Domain, Soluble)

Catalog No. ABIN1344417

This Recombinant TRAIL protein is expressed in Escherichia coli (E. coli) and has been mentioned in 3+ publications.

Quick Overview for TRAIL Protein (AA 95-281, Extracellular Domain, Soluble) (ABIN1344417)

Target: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: SDS-PAGE (SDS)

Purity: >95 % (SDS-PAGE)

Product Details

Protein Characteristics: AA 95-281, Extracellular Domain, Soluble

Specificity: Binds to human TRAIL receptors 1-4 (TRAIL-R1 to TRAIL-R4), izTRAIL does not interact with the apoptosis-inducing mouse TRAIL receptor (TRAIL-R).

Cross-Reactivity: Human

Characteristics: The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to an isoleucine zipper motif.

Endotoxin Level: <0.01EU/μg purified protein (LAL test, Lonza).

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Induces apoptosis in vitro in different human cancer cell lines with an EC50 of 5-200ng/ml, depending on the individual cell line used. Recombinant izTRAIL does not kill 4-day cultures of primary human hepatocytes (PHH) at concentrations of at least up to 1μg/ml (Ganten 2006). Good bioavailability in vivo, shows no toxic effects in mice at doses of at least up to 500μg per day (Wissink 2006).

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized. Contains 20 mM TRIS-Cl, 0.5M arginine-HCl, 100 mM NaCl, 0.02 % Tween 20.

Storage: 4 °C,-20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C.

Expiry Date: 6 months

References

Koschny, Ganten, Sykora, Haas, Sprick, Kolb, Stremmel, Walczak: "TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window." in: Hepatology (Baltimore, Md.), Vol. 45, Issue 3, pp. 649-58, (2007) (PubMed).

Ganten, Koschny, Sykora, Schulze-Bergkamen, Büchler, Haas, Schader, Untergasser, Stremmel, Walczak: "Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 8, pp. 2640-6, (2006) (PubMed).

Wissink, Verbrugge, Vink, Schader, Schaefer, Walczak, Borst, Verheij: "TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy." in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 80, Issue 2, pp. 214-22, (2006) (PubMed).

Target Details

Target: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Background: IzTRAIL is a newly available, highly active recombinant form of soluble human TRAIL. Due to a trimerizing N-terminal isoleucine zipper (iz) motif the intrinsic trimerization of TRAIL, required for apoptosis-inducing activity of TRAIL, is enhanced when compared to non-tagged soluble human TRAIL (shTRAIL). Therefore, izTRAIL is a potent inducer of apoptosis in many human cancer cells, but not normal human hepatocytes. In addition, the half-life of izTRAIL is about eight-fold higher than the half-life of shTRAIL. These properties render izTRAIL highly suitable for both, in vitro and in vivo use, particularly for studies in which investigators plan to transfer their in vitro results into an in vivo system with human cancer cells in xenotransplant settings examining susceptibility to TRAIL-induced apoptosis.

Molecular Weight: ~82kDa as stable trimers (determined by size exclusion chromatography) ~28kDa as monomer (determined by SDS-PAGE)

UniProt: P50591

Pathways: Apoptosis, Positive Regulation of Endopeptidase Activity